Drugmakers Build to Buy

If you build it, they will buy it (especially if they told you what to build to begin with).

Quite a few big biotechs and pharmaceutical companies have called on venture capital firms to help them develop companies and compounds that they can turnaround and purchase once the drugs are developed further..

Biogen Idec (NASDAQ: BIIB  ) recently hooked up with Atlas Ventures, contributing $17 million to help fund the VC's development of Ataxion with an option to purchase the company after phase one work is complete.

Celgene (NASDAQ: CELG  ) teamed up with Versant Ventures on a biotech incubator called Blueline Biosciences to develop compounds coming out of academic research in Ontario, Canada.

GlaxoSmithKline (NYSE: GSK  ) signed a deal last year with Avalon Ventures to fund as many as 10 biotech start-ups with as much as $465 million. In exchange, Glaxo has first rights on buying the new companies.

Not every large company is building with the expressed intent to buy the start-up though. Johnson & Johnson's (NYSE: JNJ  ) Jansen Pharmaceuticals has a no-strings-attached incubator where start-ups pay rent and use shared equipment. While the incubator start-ups don't have to sign a deal to be purchased later, Johnson & Johnson hopes that being familiar with the companies working on its campus will help the health-care giant offer a fair price for the biotechs should they chose to sell.

In the video below, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss the trend and how it might be good for large drug companies, but bad for investors who prefer to invest in smaller biotechs.

Identifying innovation is the key
The key to getting market crushing returns is identifying companies that are breaking all the rules. Fool co-founder David Gardner and his team have a new free report that identifies six picks for ultimate growth. Click here now for your free access.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2902426, ~/Articles/ArticleHandler.aspx, 8/27/2014 10:52:14 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement